09.03.08
Pall Corp. has acquired GeneSystems, a privately held biotechnology company that has developed its own molecular diagnostics platform. The acquisition expands Pall's Total Fluid Management (TFM) capabilities in the biopharmaceuticals process monitoring market with GeneSystems' rapid microbiological detection equipment and disposables.
Process monitoring includes the analytical tests required during biopharmaceuticals manufacturing for environmental monitoring, in-process control testing and finished product release testing, which are increasingly being scrutinized by regulatory agencies and support initiatives such as Process Analytical Technology (PAT).
GeneSystems gained market recognition for its quantitative Legionella diagnostic platform. GeneSystems has developed systems for the diagnosis of a range of pathogens, including food safety testing focused on E. coli. These systems employ advanced sample preparation methods and real-time polymerase chain reaction (PCR) technology to enable fast and high throughput along with high reproducibility analysis of multiple DNA targets. Real-time PCR detects small quantities of specific microorganisms and provides results within hours.
“We are excited by this acquisition and the increased opportunities it presents for our pharmaceutical, biotechnology, environmental monitoring, quality control and diagnostics programs,” said Eric Krasnoff, Pall chairman and chief executive officer. "Customers seek better tools for rapid testing and process monitoring. GeneSystems expands our ability to provide Total Fluid Management to meet customer's raw materials, production, testing and environmental requirements. GeneSystems’ unique technologies complement Pall's markets and global reach.”
"It is wonderful to join Pall and have the opportunity to expand on a global scale the very significant customer advantages that our team has achieved, diligently and creatively, during the last few years,” said Darryl Spurling, chief executive officer of GeneSystems.
Process monitoring includes the analytical tests required during biopharmaceuticals manufacturing for environmental monitoring, in-process control testing and finished product release testing, which are increasingly being scrutinized by regulatory agencies and support initiatives such as Process Analytical Technology (PAT).
GeneSystems gained market recognition for its quantitative Legionella diagnostic platform. GeneSystems has developed systems for the diagnosis of a range of pathogens, including food safety testing focused on E. coli. These systems employ advanced sample preparation methods and real-time polymerase chain reaction (PCR) technology to enable fast and high throughput along with high reproducibility analysis of multiple DNA targets. Real-time PCR detects small quantities of specific microorganisms and provides results within hours.
“We are excited by this acquisition and the increased opportunities it presents for our pharmaceutical, biotechnology, environmental monitoring, quality control and diagnostics programs,” said Eric Krasnoff, Pall chairman and chief executive officer. "Customers seek better tools for rapid testing and process monitoring. GeneSystems expands our ability to provide Total Fluid Management to meet customer's raw materials, production, testing and environmental requirements. GeneSystems’ unique technologies complement Pall's markets and global reach.”
"It is wonderful to join Pall and have the opportunity to expand on a global scale the very significant customer advantages that our team has achieved, diligently and creatively, during the last few years,” said Darryl Spurling, chief executive officer of GeneSystems.